首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1547371

全球白介素抑制劑市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測

Global Interleukin Inhibitors Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 128 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球白血球介素抑制劑市場需求預計將從2023年的595億美元達到2032年近2,631億美元的市場規模，2024-2032年研究期間複合年成長率為17.96%。

白細胞介素抑制劑是指能夠抑制白血球介素作用的免疫抑制劑。白細胞介素是一組由白血球合成的細胞激素。它們在免疫系統調節中發揮著至關重要的作用。白細胞介素抑制劑用於治療各種自體免疫疾病和發炎性疾病。白細胞介素抑制劑的作用是靶向細胞因子，這些細胞因子在白血球之間充當化學訊號，對抗入侵感染的反應。它們抑制這些細胞因子的活性，從而減少發炎並抑制免疫系統。

市場動態

自體免疫疾病盛行率的上升和白血球介素抑制劑的日益普及是推動白血球介素抑制劑市場的主要因素。由於安全性和有效性的提高、專利到期以及腫瘤壞死因子(TNF) 生物學名藥擴大採用催產素藥物的增加使用，人們對標靶治療的偏好日益增加，從而導致了較高的市場需求。不斷增加的新產品推出是重要的成長動力之一；例如，2019年，艾伯維公司推出了用於治療斑塊型乾癬的Skyrizi（risankizumab-rzaa），刺激了預測期內的高市場需求。此外，上市產品的標籤擴展，例如治療幼年特發性關節炎的Actemra 和治療異位性皮膚炎的dupixent 以及有利的政府舉措，以及消費者意識的提高，可能會在未來幾年為白細胞介素抑制劑市場的主要參與者創造利潤豐厚的成長機會。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球白血球介素抑制劑市場的每個細分市場進行了包容性評估。白細胞介素抑制劑產業的成長和趨勢為本研究提供了整體方法。

市場區隔

白細胞介素抑制劑市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按申請

牛皮癬
銀屑病關節炎
類風濕關節炎
氣喘
發炎性腸道疾病（IBD）
其他

按類型

白細胞介素17
白細胞介素23
白細胞介素1
白細胞介素5
白細胞介素6
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲白細胞介素抑制劑市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。白血球介素抑制劑市場的主要參與者包括強生服務公司、諾華公司、艾伯維公司、禮來公司、再生元製藥公司、阿斯特捷利康、鮑什健康、羅氏有限公司、葛蘭素史克公司、梯瓦製藥工業有限公司。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：白血球介素抑制劑公司的競爭格局

白血球介素抑制劑市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Johnson & Johnson Services Inc.

公司概況
公司收入
產品
最新動態

Novartis AG

公司概況
公司收入
產品
最新動態

AbbVie Inc.

公司概況
公司收入
產品
最新動態

Eli Lilly And Company

公司概況
公司收入
產品
最新動態

Regeneron Pharmaceuticals Inc.

公司概況
公司收入
產品
最新動態

AstraZeneca

公司概況
公司收入
產品
最新動態

Bausch Health

公司概況
公司收入
產品
最新動態

F. Hoffmann-La Roche Ltd

公司概況
公司收入
產品
最新動態

GlaxoSmithKline Plc.

公司概況
公司收入
產品
最新動態

Teva Pharmaceuticals Industries Ltd

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11215777

The global demand for Interleukin Inhibitors Market is presumed to reach the market size of nearly USD 263.1 Billion by 2032 from USD 59.5 Billion in 2023 with a CAGR of 17.96% under the study period 2024-2032.

Interleukin inhibitors refer to the immunosuppressive agents that can inhibit the interleukin's actions. Interleukins are a group of cytokines synthesized by white blood cells. They play a vital role in immune system regulation. Interleukin inhibitors are utilized to treat various autoimmune and inflammatory diseases. Interleukin inhibitors work by targeting cytokines that act as chemical signals between the white blood cells against the response of invading infection. They subdue the activity of these cytokines, thus reducing inflammation and suppressing the immune system.

MARKET DYNAMICS

The rising prevalence of autoimmune diseases and increasing adoption of interleukin inhibitors is the major factor driving the interleukin inhibitors market. The growing preference for targeted therapies is increasing due to their improved safety and efficacy profiles, patent expiry, and increased adoption of a biosimilar in Tumor Necrosis Factor (TNF) into the augmented usage of oxytocic drugs, which leads to high market demand. The rising new product launches are one of the important growth rendering drivers; for instance, in 2019, AbbVie, Inc. had launched Skyrizi (risankizumab-rzaa) for the treatment of plaque psoriasis treatment is stimulating the high market demand in the forecast period. Moreover, label expansions of marketed products, such as actemra for juvenile idiopathic arthritis and dupixent for atopic dermatitis and favorable government initiatives, and increasing consumer awareness is likely to create lucrative growth opportunities for key players of the interleukin inhibitors market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Interleukin Inhibitors. The growth and trends of Interleukin Inhibitors industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Interleukin Inhibitors market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

Psoriasis
Psoriatic Arthritis
Rheumatoid Arthritis
Asthma
Inflammatory Bowel Disease (IBD)
Others

By Type

IL-17
IL-23
IL-1
IL-5
IL-6
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Interleukin Inhibitors market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Interleukin Inhibitors market include Johnson & Johnson Services Inc., Novartis AG, AbbVie Inc., Eli Lilly And Company, Regeneron Pharmaceuticals Inc., AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc., Teva Pharmaceuticals Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. INTERLEUKIN INHIBITORS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Application
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL INTERLEUKIN INHIBITORS MARKET ANALYSIS BY APPLICATION

5.1. Overview By Application
5.2. Historical and Forecast Data Analysis By Application
5.3. Psoriasis Historic and Forecast Sales By Regions
5.4. Psoriatic Arthritis Historic and Forecast Sales By Regions
5.5. Rheumatoid Arthritis Historic and Forecast Sales By Regions
5.6. Asthma Historic and Forecast Sales By Regions
5.7. Inflammatory Bowel Disease (IBD) Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL INTERLEUKIN INHIBITORS MARKET ANALYSIS BY TYPE

6.1. Overview By Type
6.2. Historical and Forecast Data Analysis By Type
6.3. IL-17 Historic and Forecast Sales By Regions
6.4. IL-23 Historic and Forecast Sales By Regions
6.5. IL-1 Historic and Forecast Sales By Regions
6.6. IL-5 Historic and Forecast Sales By Regions
6.7. IL-6 Historic and Forecast Sales By Regions
6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL INTERLEUKIN INHIBITORS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE INTERLEUKIN INHIBITORS COMPANIES

8.1. Interleukin Inhibitors Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF INTERLEUKIN INHIBITORS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Johnson & Johnson Services Inc.
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Novartis AG
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. AbbVie Inc.
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Eli Lilly And Company
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. Regeneron Pharmaceuticals Inc.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. AstraZeneca
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Bausch Health
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. F. Hoffmann-La Roche Ltd
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. GlaxoSmithKline Plc.
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Teva Pharmaceuticals Industries Ltd
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments